Synthesis and preclinical evaluation of an Al(18)F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand

The aim of this study was to synthesize and preclinically evaluate an (18)F-PSMA positron emission tomography (PET) tracer. Prostate-specific membrane antigen (PSMA) specificity, biodistribution, and dosimetry in healthy and tumor-bearing mice were determined.

Several conditions for the labeling of (18)F-PSMA-11 via (18)F-AlF-complexation were screened to study the influence of reaction temperature, peptide amount, ethanol volume, and reaction time. After synthesis optimization, biodistribution and dosimetry studies were performed in C57BL6 mice. For proof of PSMA-specificity, mice were implanted with PSMA-negative (PC3) and PSMA-positive (LNCaP) tumors in contralateral flanks. Static and dynamic microPET/computed tomography (CT) imaging was performed.

Quantitative labeling yields could be achieved with >97 % radiochemical purity. The (18)F-PSMA-11 uptake was more than 24-fold higher in PSMA-high LNCaP than in PSMA-low PC3 tumors (18.4 ± 3.3 %ID/g and 0.795 ± 0.260 %ID/g, respectively; p < 4.2e-5). Results were confirmed by ex vivo gamma counter analysis of tissues after the last imaging time point. The highest absorbed dose was reported for the kidneys. The maximum effective dose for an administered activity of 200 MBq was 1.72 mSv.

(18)F-PSMA-11 using direct labeling of chelate-attached peptide with aluminum-fluoride detected PSMA-expressing tumors with high tumor-to-liver ratios. The kidneys were the dose-limiting organs. Even by applying the most stringent dosimetric calculations, injected activities of up to 0.56 GBq are feasible.

European journal of nuclear medicine and molecular imaging. 2016 Jun 22 [Epub ahead of print]

Stefano Boschi, Jason T Lee, Seval Beykan, Roger Slavik, Liu Wei, Claudio Spick, Uta Eberlein, Andreas K Buck, Filippo Lodi, Gianfranco Cicoria, Johannes Czernin, Michael Lassmann, Stefano Fanti, Ken Herrmann

Department of Nuclear Medicine, S.Orsola-Malpighi University Hospital, Via Massarenti 9, 40138, Bologna, Italy., Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, USA., Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany., Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave. CHS AR-255, Los Angeles, CA, 90095, USA., Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave. CHS AR-255, Los Angeles, CA, 90095, USA., Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave. CHS AR-255, Los Angeles, CA, 90095, USA., Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany., Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany., Department of Nuclear Medicine, S.Orsola-Malpighi University Hospital, Via Massarenti 9, 40138, Bologna, Italy., Department of Medical Physics, S. Orsola-Malpighi University Hospital, Bologna, Italy., Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave. CHS AR-255, Los Angeles, CA, 90095, USA., Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany., Department of Nuclear Medicine, S.Orsola-Malpighi University Hospital, Via Massarenti 9, 40138, Bologna, Italy., Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany. .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe